- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Do | BMS walks away from $80M neurodegeneration bet after phase 1 | ||
| Do | BioMarin inks up to $475M deal to challenge Fabry ERT incumbents | ||
| Do | Flagship brings 3 biotech platforms together to launch AI drug discovery player Etcelera | ||
| Do | Why researchers may have found the biological culprit behind Angelman syndrome | ||
| Do | Ascletis' challenger to Lilly's Foundayo hits goals in phase 2 diabetes trial | ||
| 28.10. | Genmab's $8B Merus bet delivers as bispecific combo halves risk of death in phase 3 | ||
| 28.10. | FDA's rare disease framework aims to 'stand the test of time' | ||
| 28.10. | 'The patient need is enormous': Syntax programs stem cells into pancreatic beta cells in 4 days | ||
| 28.10. | Biogen CEO tells analysts he's focused on early-stage R&D as 'we were not very good with that' | ||
| 28.10. | Lilly's retatrutide bests Ozempic on blood sugar, weight loss in phase 3 diabetes showdown | ||
| 28.10. | As ADC king Enhertu rewrites HER2 breast cancer care, the hunt for what comes next is barely out the gate | ||
| 28.10. | GSK predicts 'some limited impact' to UK roles as restructuring rolls on | ||
| 28.10. | Astellas makes $1.3B bet on Audax's preclinical push to reverse decades of IL-12 woes | ||
| 28.10. | The 2026 Biotech Graveyard | ||
| 27.10. | From RAS rivalries to leaked cancer vaccine readouts, ESMO brought the data drama | ||
| 27.10. | Artiva lays off 94% of staff after deaths and durability sink autoimmune cell therapy | ||
| 27.10. | Parkinson's-focused Aspen and bispecific biotech Bambusa both shoot for $134M IPOs | ||
| 27.10. | Corxel claims oral obesity drug is in the 'right lane' as biotech plans SPAC route to Nasdaq | ||
| 27.10. | Novartis CEO keeps faith in Avidity deal despite taking $1.9B hit from del-desiran fail | ||
| 27.10. | GSK's B7-H3 ADC drives 67% cancer risk reduction in Hansoh's phase 3 China trial | ||
| 27.10. | BMS joins 3-year partnership to boost participation in cancer trials | ||
| 26.10. | Boehringer, Microsoft team up to explore digital patient twins for clinical trials | ||
| 26.10. | Anthropic lays out drug R&D ambitions, risks in mammoth IPO filing | ||
| 26.10. | Windward Bio | ||
| 26.10. | ESMO: Why Incyte sees itself 'neck and neck' with RevMed in KRAS G12D pancreatic cancer race |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.